Literature DB >> 23062653

Is BRAF mutation associated with lymph node metastasis in patients with papillary thyroid cancer?

Kathleen C Lee1, Carol Li, Eric B Schneider, Yongchun Wang, Helina Somervell, Matthew Krafft, Christopher B Umbricht, Martha A Zeiger.   

Abstract

BACKGROUND: Some have proposed using V600E BRAF mutation status to dictate the surgical management of patients with papillary thyroid cancer (PTC). However, well-designed studies examining BRAF association with aggressive clinicopathologic features of PTC, including the presence of lymph node metastases (LNM), in patients who have undergone routine central lymph node dissection (CLND), are lacking.
METHODS: Under institutional review board approval, 63 patients diagnosed with PTC on fine-needle aspiration who underwent total thyroidectomy and CLND were included. BRAF mutation status was determined in fresh frozen or intraoperative fine-needle aspiration samples with a colorimetric assay. Associations between BRAF mutation status and clinicopathologic features of PTC were examined using Chi-square and multivariate logistic regression analyses.
RESULTS: BRAF mutation was found to be significantly associated with race only on Chi-square analysis. BRAF mutation was not found to be significantly associated with the presence of LNM (P = .167). On multivariate analysis, only size and venous/lymphatic invasion were significantly associated with LNM.
CONCLUSION: This small series underscores the prematurity in utilizing BRAF mutation status to determine the surgical management of patients with PTC, specifically whether or not to perform a CLND.
Copyright © 2012 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23062653      PMCID: PMC3715093          DOI: 10.1016/j.surg.2012.08.019

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  24 in total

1.  Papillary cancer of the thyroid; a review of 25 years of experience.

Authors:  E L FRAZELL; F W FOOTE
Journal:  Cancer       Date:  1958 Sep-Oct       Impact factor: 6.860

2.  A new technology for mutation detection.

Authors:  W Shackelford; S Deng; K Murayama; J Wang
Journal:  Ann N Y Acad Sci       Date:  2004-06       Impact factor: 5.691

3.  Optimizing surgical treatment of papillary thyroid carcinoma associated with BRAF mutation.

Authors:  Linwah Yip; Marina N Nikiforova; Sally E Carty; John H Yim; Michael T Stang; Mitchell J Tublin; Shane O Lebeau; Steven P Hodak; Jennifer B Ogilvie; Yuri E Nikiforov
Journal:  Surgery       Date:  2009-12       Impact factor: 3.982

4.  Evolution in the surgical management of well-differentiated thyroid cancer or not: to dissect or not dissect the central lymph node compartment.

Authors:  Martha A Zeiger
Journal:  J Surg Oncol       Date:  2010-02-01       Impact factor: 3.454

5.  Preoperative BRAF mutation has different predictive values for lymph node metastasis according to tumor size.

Authors:  Yoon Kyoung So; Young-Ik Son; Joo Yeon Park; Chung-Hwan Baek; Han-Sin Jeong; Man Ki Chung
Journal:  Otolaryngol Head Neck Surg       Date:  2011-07-12       Impact factor: 3.497

6.  The role of molecular markers and tumor histological type in central lymph node metastasis of papillary thyroid carcinoma.

Authors:  Lorien Paulson; Maisie Shindo; Kathryn Schuff; Christopher Corless
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2012-01

7.  BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer.

Authors:  Mingzhao Xing; William H Westra; Ralph P Tufano; Yoram Cohen; Eli Rosenbaum; Kerry J Rhoden; Kathryn A Carson; Vasily Vasko; Alexandr Larin; Giovanni Tallini; Sara Tolaney; Elizabeth H Holt; Pei Hui; Christopher B Umbricht; Shehzad Basaria; Marge Ewertz; Anthony P Tufaro; Joseph A Califano; Matthew D Ringel; Martha A Zeiger; David Sidransky; Paul W Ladenson
Journal:  J Clin Endocrinol Metab       Date:  2005-09-20       Impact factor: 5.958

8.  BRAF(V600E) mutation is associated with an increased risk of nodal recurrence requiring reoperative surgery in patients with papillary thyroid cancer.

Authors:  Christine J O'Neill; Martyn Bullock; Angela Chou; Stan B Sidhu; Leigh W Delbridge; Bruce G Robinson; Anthony J Gill; Diana L Learoyd; Roderick Clifton-Bligh; Mark S Sywak
Journal:  Surgery       Date:  2010-12       Impact factor: 3.982

9.  Correlation between the BRAF V600E mutation and tumor invasiveness in papillary thyroid carcinomas smaller than 20 millimeters: analysis of 1060 cases.

Authors:  Fulvio Basolo; Liborio Torregrossa; Riccardo Giannini; Mario Miccoli; Cristiana Lupi; Elisa Sensi; Piero Berti; Rossella Elisei; Paolo Vitti; Angelo Baggiani; Paolo Miccoli
Journal:  J Clin Endocrinol Metab       Date:  2010-07-14       Impact factor: 5.958

10.  BRAF mutations in an Italian cohort of thyroid cancers.

Authors:  Laura Fugazzola; Deborah Mannavola; Valentina Cirello; Guia Vannucchi; Marina Muzza; Leonardo Vicentini; Paolo Beck-Peccoz
Journal:  Clin Endocrinol (Oxf)       Date:  2004-08       Impact factor: 3.478

View more
  23 in total

Review 1.  The prognostic implication and potential role of BRAF mutation in the decision to perform elective neck dissection for thyroid cancer.

Authors:  Jin Woo Lee; Bon Seok Koo
Journal:  Gland Surg       Date:  2013-11

Review 2.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.

Authors:  Bryan R Haugen; Erik K Alexander; Keith C Bible; Gerard M Doherty; Susan J Mandel; Yuri E Nikiforov; Furio Pacini; Gregory W Randolph; Anna M Sawka; Martin Schlumberger; Kathryn G Schuff; Steven I Sherman; Julie Ann Sosa; David L Steward; R Michael Tuttle; Leonard Wartofsky
Journal:  Thyroid       Date:  2016-01       Impact factor: 6.568

Review 3.  The association between BRAF (V600E) mutation and pathological features in PTC.

Authors:  Xin Liu; Kangkang Yan; Xuejun Lin; Longyu Zhao; Wenxiu An; Chunpeng Wang; Xiaodong Liu
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-01-04       Impact factor: 2.503

Review 4.  Clinical application of molecular testing of fine-needle aspiration specimens in thyroid nodules.

Authors:  Linwah Yip; Robert L Ferris
Journal:  Otolaryngol Clin North Am       Date:  2014-06-12       Impact factor: 3.346

5.  Clinical and therapeutic implications of Sprouty2 feedback dysregulation in BRAF V600E-mutation-positive papillary thyroid cancer.

Authors:  Linda A Dultz; Shumon Dhar; Jennifer B Ogilvie; Keith S Heller; Dafna Bar-Sagi; Kepal N Patel
Journal:  Surgery       Date:  2013-10-02       Impact factor: 3.982

6.  Changes in the clinicopathological characteristics and outcomes of thyroid cancer in Korea over the past four decades.

Authors:  Bo Youn Cho; Hoon Sung Choi; Young Joo Park; Jung Ah Lim; Hwa Young Ahn; Eun Kyung Lee; Kyung Won Kim; Ka Hee Yi; June-Key Chung; Yeo-Kyu Youn; Nam Han Cho; Do Joon Park; Chang-Soon Koh
Journal:  Thyroid       Date:  2013-06-21       Impact factor: 6.568

7.  Tumor genotype determines phenotype and disease-related outcomes in thyroid cancer: a study of 1510 patients.

Authors:  Linwah Yip; Marina N Nikiforova; Jenny Y Yoo; Kelly L McCoy; Michael T Stang; Michaele J Armstrong; Kristina J Nicholson; N Paul Ohori; Christopher Coyne; Steven P Hodak; Robert L Ferris; Shane O LeBeau; Yuri E Nikiforov; Sally E Carty
Journal:  Ann Surg       Date:  2015-09       Impact factor: 12.969

8.  The BRAF V600E mutation in papillary thyroid cancer with positive or suspected pre-surgical cytological finding is not associated with advanced stages or worse prognosis.

Authors:  Daniele Barbaro; Roberto Mario Incensati; Gabriele Materazzi; Giuseppe Boni; Mariano Grosso; Erica Panicucci; Paola Lapi; Cristina Pasquini; Paolo Miccoli
Journal:  Endocrine       Date:  2013-08-08       Impact factor: 3.633

9.  Detection of Circulating BRAF(V600E) in Patients with Papillary Thyroid Carcinoma.

Authors:  Carrie C Lubitz; Sareh Parangi; Tammy M Holm; M Jordana Bernasconi; Aislyn P Schalck; Hyunsuk Suh; Konstantinos P Economopoulos; Viswanath Gunda; Samuel E Donovan; Peter M Sadow; Lori J Wirth; Ryan J Sullivan; David J Panka
Journal:  J Mol Diagn       Date:  2015-11-26       Impact factor: 5.568

10.  Predictive Value of BRAFV600E Mutation for Lymph Node Metastasis in Papillary Thyroid Cancer: A Meta-analysis.

Authors:  Jing-Yong Song; Shi-Ran Sun; Fang Dong; Tao Huang; Bin Wu; Jing Zhou
Journal:  Curr Med Sci       Date:  2018-10-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.